« Previous
Next »
Seminars in Oncology
Volume 36
, Pages
S2-S16
, August 2009
Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications
-
Pharmacogenetic determinants of central nervous system (CNS) relapse. VDR, vitamin D receptor; TYM, thymidylate; TYMS, thymidylate synthetase. This research was originally published in Blood. Rocha JC
Pharmacogenetic determinants of central nervous system (CNS) relapse. VDR, vitamin D receptor; TYM, thymidylate; TYMS, thymidylate synthetase. This research was originally published in Blood. Rocha JC, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752-8. © the American Society of Hematology.
-
Response Adapted Therapy study for the treatment of central nervous system (CNS) relapse of aggressive lymphoma. AraC, cytarabine; ASCT, autologous stem cell transplant; CR, complete response; ECOG, EResponse Adapted Therapy study for the treatment of central nervous system (CNS) relapse of aggressive lymphoma. AraC, cytarabine; ASCT, autologous stem cell transplant; CR, complete response; ECOG, Eastern Cooperative Oncology Group; ETO, etoposide; HD-BCNU, high-dose carmustine; IFO, ifosfamide; LC, liposomal cytarabine; NC, no change; MTX, methotrexate; NHL, non-Hodgkin lymphoma; OS, overall survival; PR, partial response; RR, response rate; TTF, time to treatment failure; TT, thiotepa; SC, subcutaneous.
STATEMENT OF CONFLICT OF INTEREST: The authors received honoraria for lectures from Mundipharma.
PII: S0093-7754(09)00092-X
doi: 10.1053/j.seminoncol.2009.05.002
« Previous
Next »
Seminars in Oncology
Volume 36
, Pages
S2-S16
, August 2009
